{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:50:21Z","timestamp":1790524221680,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,6,26]],"date-time":"2010-06-26T00:00:00Z","timestamp":1277510400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10495-010-0521-9","type":"journal-article","created":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T12:02:23Z","timestamp":1277467343000},"page":"1256-1269","source":"Crossref","is-referenced-by-count":31,"title":["Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells"],"prefix":"10.1007","volume":"15","author":[{"given":"Eun-Sil","family":"Sung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Seong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junho","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Hee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,26]]},"reference":[{"key":"521_CR1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2637","volume":"7","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001\u20131012","journal-title":"Nat Rev Drug Discov"},{"key":"521_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14712590903319656","volume":"10","author":"NL Fox","year":"2010","unstructured":"Fox NL, Humphreys R, Luster TA, Klein J, Gallant G (2010) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert Opin Biol Ther 10:1\u201318","journal-title":"Expert Opin Biol Ther"},{"key":"521_CR3","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrc2465","volume":"8","author":"RW Johnstone","year":"2008","unstructured":"Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782\u2013798","journal-title":"Nat Rev Cancer"},{"key":"521_CR4","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V96.12.3900","volume":"96","author":"J Wen","year":"2000","unstructured":"Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96:3900\u20133906","journal-title":"Blood"},{"key":"521_CR5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1023\/A:1026131425204","volume":"8","author":"XS Hao","year":"2003","unstructured":"Hao XS, Hao JH, Liu FT, Newland AC, Jia L (2003) Potential mechanisms of leukemia cell resistance to TRAIL-induced apopotosis. Apoptosis 8:601\u2013607","journal-title":"Apoptosis"},{"key":"521_CR6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2141.2004.05289.x","volume":"128","author":"H Hasegawa","year":"2005","unstructured":"Hasegawa H, Yamada Y, Harasawa H et al (2005) Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br J Haematol 128:253\u2013265","journal-title":"Br J Haematol"},{"key":"521_CR7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1365-2141.2000.02328.x","volume":"111","author":"C Adida","year":"2000","unstructured":"Adida C, Recher C, Raffoux E et al (2000) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111:196\u2013203","journal-title":"Br J Haematol"},{"key":"521_CR8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/386517a0","volume":"386","author":"M Thome","year":"1997","unstructured":"Thome M, Schneider P, Hofmann K et al (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517\u2013521","journal-title":"Nature"},{"key":"521_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2008.02.001","volume":"11","author":"A Thorburn","year":"2008","unstructured":"Thorburn A, Behbakht K, Ford H (2008) TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updates 11:17\u201324","journal-title":"Drug Resist Updates"},{"key":"521_CR10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10495-007-0081-9","volume":"12","author":"CA Dumitru","year":"2007","unstructured":"Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E (2007) Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 12:1533\u20131541","journal-title":"Apoptosis"},{"key":"521_CR11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2005.05656.x","volume":"130","author":"GV Georgakis","year":"2005","unstructured":"Georgakis GV, Li Y, Humphreys R et al (2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130:501\u2013510","journal-title":"Br J Haematol"},{"key":"521_CR12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s10495-006-8048-9","volume":"11","author":"AF Kabore","year":"2006","unstructured":"Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB (2006) The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 11:1175\u20131193","journal-title":"Apoptosis"},{"key":"521_CR13","doi-asserted-by":"crossref","first-page":"9394","DOI":"10.1158\/0008-5472.CAN-08-2815","volume":"68","author":"PL Tazzari","year":"2008","unstructured":"Tazzari PL, Tabellini G, Ricci F et al (2008) Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res 68:9394\u20139403","journal-title":"Cancer Res"},{"key":"521_CR14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V98.3.795","volume":"98","author":"CS Mitsiades","year":"2001","unstructured":"Mitsiades CS, Treon SP, Mitsiades N et al (2001) TRAIL\/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98:795\u2013804","journal-title":"Blood"},{"key":"521_CR15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.yexcr.2009.02.024","volume":"315","author":"SJ Park","year":"2009","unstructured":"Park SJ, Kim MJ, Kim HB et al (2009) Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Exp Cell Res 315:1809\u20131818","journal-title":"Exp Cell Res"},{"key":"521_CR16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2009.03.013","volume":"280","author":"N Batty","year":"2009","unstructured":"Batty N, Malouf GG, Issa JP (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280:192\u2013200","journal-title":"Cancer Lett"},{"key":"521_CR17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.exphem.2007.06.014","volume":"35","author":"L Lagneaux","year":"2007","unstructured":"Lagneaux L, Gillet N, Stamatopoulos B et al (2007) Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 35:1527\u20131537","journal-title":"Exp Hematol"},{"key":"521_CR18","first-page":"855","volume":"28","author":"G Iacomino","year":"2008","unstructured":"Iacomino G, Medici MC, Russo GL (2008) Valproic acid sensitizes K562 erythroleukemia cells to TRAIL\/Apo2L-induced apoptosis. Anticancer Res 28:855\u2013864","journal-title":"Anticancer Res"},{"key":"521_CR19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.biocel.2007.03.009","volume":"39","author":"M Tsapis","year":"2007","unstructured":"Tsapis M, Lieb M, Manzo F et al (2007) HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 39:1500\u20131509","journal-title":"Int J Biochem Cell Biol"},{"key":"521_CR20","first-page":"1273","volume":"2","author":"RR Rosato","year":"2003","unstructured":"Rosato RR, Almenara JA, Dai Y, Grant S (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2:1273\u20131284","journal-title":"Mol Cancer Ther"},{"key":"521_CR21","first-page":"1125","volume":"16","author":"S Shankar","year":"2005","unstructured":"Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK (2005) Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16:1125\u20131138","journal-title":"Int J Mol Med"},{"key":"521_CR22","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-07-0812","volume":"67","author":"ST Nawrocki","year":"2007","unstructured":"Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA (2007) Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res 67:6987\u20136994","journal-title":"Cancer Res"},{"key":"521_CR23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.cdd.4401649","volume":"12","author":"M MacFarlane","year":"2005","unstructured":"MacFarlane M, Inoue S, Kohlhaas SL et al (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12:773\u2013782","journal-title":"Cell Death Differ"},{"key":"521_CR24","doi-asserted-by":"crossref","first-page":"11265","DOI":"10.1158\/0008-5472.CAN-05-2801","volume":"65","author":"M MacFarlane","year":"2005","unstructured":"MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65:11265\u201311270","journal-title":"Cancer Res"},{"key":"521_CR25","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1074\/jbc.M410660200","volume":"280","author":"RF Kelley","year":"2005","unstructured":"Kelley RF, Totpal K, Lindstrom SH et al (2005) Receptor-selective mutants of apoptosis-inducing ligand 2\/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280:2205\u20132212","journal-title":"J Biol Chem"},{"key":"521_CR26","doi-asserted-by":"crossref","first-page":"8634","DOI":"10.1073\/pnas.0510187103","volume":"103","author":"AM Sloot van der","year":"2006","unstructured":"van der Sloot AM, Tur V, Szegezdi E et al (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 103:8634\u20138639","journal-title":"Proc Natl Acad Sci USA"},{"key":"521_CR27","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1158\/0008-5472.CAN-05-4563","volume":"66","author":"S Inoue","year":"2006","unstructured":"Inoue S, Mai A, Dyer MJ, Cohen GM (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 66:6785\u20136792","journal-title":"Cancer Res"},{"key":"521_CR28","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1158\/1535-7163.MCT-09-0235","volume":"8","author":"ES Sung","year":"2009","unstructured":"Sung ES, Park KJ, Lee SH et al (2009) A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Mol Cancer Ther 8:2276\u20132285","journal-title":"Mol Cancer Ther"},{"key":"521_CR29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.molimm.2009.09.041","volume":"47","author":"SH Lee","year":"2010","unstructured":"Lee SH, Park DW, Sung ES, Park HR, Kim JK, Kim YS (2010) Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity. Mol Immunol 47:816\u2013824","journal-title":"Mol Immunol"},{"key":"521_CR30","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1158\/0008-5472.CAN-07-2508","volume":"68","author":"S Huang","year":"2008","unstructured":"Huang S, Sinicrope FA (2008) BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 68:2944\u20132951","journal-title":"Cancer Res"},{"key":"521_CR31","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1158\/0008-5472.CAN-06-4766","volume":"67","author":"KJ Park","year":"2007","unstructured":"Park KJ, Lee SH, Kim TI et al (2007) A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res 67:7327\u20137334","journal-title":"Cancer Res"},{"key":"521_CR32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbrc.2009.03.095","volume":"382","author":"KJ Park","year":"2009","unstructured":"Park KJ, Lee SH, Lee CH et al (2009) Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. Biochem Biophys Res Commun 382:726\u2013729","journal-title":"Biochem Biophys Res Commun"},{"key":"521_CR33","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1535-7163.MCT-05-0262","volume":"4","author":"L Galligan","year":"2005","unstructured":"Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG (2005) Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 4:2026\u20132036","journal-title":"Mol Cancer Ther"},{"key":"521_CR34","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428190802353591","volume":"49","author":"TC Chou","year":"2008","unstructured":"Chou TC (2008) Preclinical versus clinical drug combination studies. Leuk Lymphoma 49:2059\u20132080","journal-title":"Leuk Lymphoma"},{"key":"521_CR35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1189\/jlb.0103004","volume":"74","author":"P Secchiero","year":"2003","unstructured":"Secchiero P, Milani D, Gonelli A et al (2003) Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. J Leukoc Biol 74:223\u2013232","journal-title":"J Leukoc Biol"},{"key":"521_CR36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/sj.bjc.6602487","volume":"92","author":"L Pukac","year":"2005","unstructured":"Pukac L, Kanakaraj P, Humphreys R et al (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430\u20131441","journal-title":"Br J Cancer"},{"key":"521_CR37","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-03-2629","volume":"64","author":"F Guo","year":"2004","unstructured":"Guo F, Sigua C, Tao J et al (2004) Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L\/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 64:2580\u20132589","journal-title":"Cancer Res"},{"key":"521_CR38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","volume":"125","author":"C Zhang","year":"2005","unstructured":"Zhang C, Richon V, Ni X, Talpur R, Duvic M (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Investig Dermatol 125:1045\u20131052","journal-title":"J Investig Dermatol"},{"issue":"Suppl 2","key":"521_CR39","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","volume":"11","author":"S Inoue","year":"2004","unstructured":"Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(Suppl 2):S193\u2013S206","journal-title":"Cell Death Differ"},{"key":"521_CR40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1067\/msy.2001.115897","volume":"130","author":"A Hernandez","year":"2001","unstructured":"Hernandez A, Thomas R, Smith F et al (2001) Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 130:265\u2013272","journal-title":"Surgery"},{"key":"521_CR41","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/sj.onc.1205258","volume":"21","author":"S Fulda","year":"2002","unstructured":"Fulda S, Meyer E, Debatin KM (2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21:2283\u20132294","journal-title":"Oncogene"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-010-0521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-010-0521-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-010-0521-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T03:59:20Z","timestamp":1591415960000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-010-0521-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,26]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s10495-010-0521-9","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,26]]}}}